Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.
Glucosylceramides (GlcCer) are involved in the regulation of Cryptococcus neoformans virulence. In the present study, we demonstrate that passive immunization with a monoclonal antibody to GlcCer significantly reduces host inflammation and prolongs the survival of mice lethally infected with C. neoformans, revealing a potential therapeutic strategy to control cryptococcosis.
Rodrigues
Marcio L
ML
Instituto de Microbiologia Professor Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, Brazil. marcio@micro.ufrj.br
Shi
Li
L
Barreto-Bergter
Eliana
E
Nimrichter
Leonardo
L
Farias
Sandra E
SE
Rodrigues
Elaine G
EG
Travassos
Luiz R
LR
Nosanchuk
Joshua D
JD
D000818:Animals; D000908:Antibodies, Fungal / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000946:Antigens, Fungal / Q000276:immunology*; D002554:Cerebrosides / Q000276:immunology*; D003453:Cryptococcosis / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D003455:Cryptococcus neoformans / Q000276:immunology*; D005260:Female; D051379:Mice; D008805:Mice, Inbred A
D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D000946:Antigens, Fungal; D002554:Cerebrosides; C013870:ceramide monohexoside
Clin Exp Immunol. 1989 Dec;78(3):412-7
2612053
Infect Immun. 1987 Mar;55(3):742-8
3546139
Clin Exp Immunol. 1996 May;104(2):208-14
8625510
J Immunol. 1997 Jan 15;158(2):790-9
8992996
J Antimicrob Chemother. 1997 Oct;40(4):475-83
9372415
J Infect Dis. 1998 Jun;177(6):1639-46
9607844
Antimicrob Agents Chemother. 1998 Jun;42(6):1437-46
9624491
Mol Cell Biol. 1999 Jan;19(1):745-50
9858597
Infect Immun. 2005 Feb;73(2):1141-50
15664957
Med Mycol. 2005 Feb;43(1):27-38
15712606
Antimicrob Agents Chemother. 2005 Mar;49(3):952-8
15728888
Br Med Bull. 2004;72:99-118
15838017
Microbes Infect. 2005 Apr;7(4):789-98
15823515
Clin Diagn Lab Immunol. 2005 Sep;12(9):1063-8
16148172
Infect Immun. 2005 Dec;73(12):7860-8
16299276
J Clin Invest. 2006 Jun;116(6):1481-3
16741574
J Clin Invest. 2006 Jun;116(6):1651-9
16741577
Infect Immun. 2006 Sep;74(9):5302-10
16926424
Infect Dis Clin North Am. 2006 Sep;20(3):507-44, v-vi
16984867
Eukaryot Cell. 2007 Jan;6(1):48-59
17114598
Infect Immun. 2007 Nov;75(11):5085-94
17606600
Chem Phys Lipids. 1987 Jan-Feb;43(1):1-12
3555875
Microbes Infect. 1999 Apr;1(4):293-301
10602663
Infect Immun. 2000 Mar;68(3):1649-54
10678984
Chest. 2000 Apr;117(4):1162-72
10767254
Infect Immun. 2000 Dec;68(12):7049-60
11083830
J Immunol. 2001 Feb 1;166(3):2100-7
11160261
Infect Immun. 2001 May;69(5):3410-2
11292764
Infect Immun. 2001 Oct;69(10):6445-55
11553589
Glycobiology. 2002 Apr;12(4):251-60
12042248
FEBS Lett. 2002 Aug 14;525(1-3):59-64
12163162
J Clin Invest. 2003 Oct;112(8):1164-75
14561701
J Biol Chem. 2004 Feb 6;279(6):3900-5
14604982
FEBS Lett. 2004 Mar 12;561(1-3):137-43
15013765
Nat Rev Microbiol. 2003 Oct;1(1):17-24
15040176
An Acad Bras Cienc. 2004 Mar;76(1):67-84
15048196
Microbes Infect. 2004 Jun;6(7):657-65
15158773
Front Biosci. 1998 Feb 1;3:d136-51
9445465
Nat Rev Microbiol. 2004 Sep;2(9):695-703
15372080
Infect Immun. 1992 Nov;60(11):4534-41
1398966